ARPA-H gene editing program THRIVE awards $160 million to seven research teams tasked with building scalable base-editing ...

Ionis Pharmaceuticals is a leader in RNA-based therapies. Its spinal muscular atrophy drug Spinraza, marketed by partner Biogen, is the first RNA-based therapy to achieve blockbuster status. The ...

Rat disease models have played an integral role in scientific discovery and cancer research, including Nobel Prize–winning ...

Human genetics has become the primary engine for identifying lipid-lowering drug targets and predicting therapeutic success or failure. Monogenic family studies and population-based sequencing ...

RNA has emerged as one of the most promising molecules in modern medicine, enabling advances from mRNA vaccines and gene ...

Persistence Market Research, a leading management consulting firm, has released this update on the gene editing market. Gene editing technologies enable ...

New England Biolabs (NEB®) has launched the NEBNext Companion Module for Oxford Nanopore Technologies Direct RNA Sequencing.

Persistence Market Research, a leading management consulting firm, has released this update on the gene editing market. Gene ...

University of Arkansas scientists study soybean cyst nematode proteins to develop gene-edited soybean varieties resistant to ...

Single-cell RNA-seq AI analysis has become the default way to make sense of the millions of expression measurements a single experiment can now generate. Turning raw sequencing counts into ...

The collaboration leverages Colossal's marsupial de-extinction and conservation biotechnology platform to save the Tasmanian devil from a contagious cancer that has driven 80% population declines ...